Botox for Chronic Migraine: How It Works, Who Qualifies, and What to Expect

OnabotulinumtoxinA, marketed under the brand name Botox, is approved by the United States Food and Drug Administration for the prevention of chronic migraine in adults. It is the only neuromodulatory treatment with this specific approval and one of the most effective preventive options available for people with chronic migraine who have not responded adequately to oral preventive medications. Despite its widespread recognition from cosmetic applications, Botox for migraine is a distinct clinical application with specific indications, injection protocols, and mechanisms that differ from its use in aesthetics.

What Botox Is and How It Works in Migraine

Botox is a neurotoxin produced by the bacterium Clostridium botulinum. In cosmetic applications, it works by blocking the release of acetylcholine at neuromuscular junctions, preventing muscle contraction and reducing wrinkles. In migraine, the mechanism is different. When injected into the pericranial and cervical muscles involved in migraine, Botox is taken up by sensory nerve terminals and inhibits the release of neuropeptides including calcitonin gene-related peptide and substance P.

By reducing CGRP release from trigeminal nerve terminals, Botox directly targets one of the key mediators of neurogenic inflammation and trigeminovascular activation that drive chronic migraine. This mechanism is distinct from its neuromuscular effects and explains why migraine benefit is not simply a result of relaxing tense muscles.

Who Qualifies for Botox Treatment

Botox is approved specifically for chronic migraine, defined as headache occurring on fifteen or more days per month with at least eight of those days meeting criteria for migraine. It is not approved for episodic migraine with fewer than fifteen headache days per month, and insurance coverage typically requires documentation of chronic migraine meeting this frequency threshold.

In addition to the diagnosis of chronic migraine, most insurance plans require documentation of failure of at least two or more oral preventive medications before approving Botox coverage. This step therapy requirement reflects the position of Botox as a second-line treatment for people who have not achieved adequate control with standard preventive options.

The PREEMPT Protocol

The injection protocol used for chronic migraine treatment was established in the PREEMPT clinical trials, two large randomized controlled trials that formed the basis for FDA approval. The PREEMPT protocol involves injections at thirty-one fixed sites across the forehead, temples, back of the head, neck, and upper shoulders, with additional injections at sites of maximal pain at the clinician's discretion.

The total dose in a standard PREEMPT treatment is 155 to 195 units. Treatment is administered every twelve weeks. Clinical response is assessed after two treatment cycles, approximately six months of treatment, before concluding whether Botox is effective for a given patient.

What to Expect From Treatment

Most people who respond to Botox do not experience the full benefit after the first treatment. The gradual reduction in migraine frequency typically develops over the first two to three treatment cycles. Patients who experience a modest response after the first cycle may experience greater benefit after the second or third.

Common side effects include temporary soreness at injection sites, mild neck weakness, and occasional eyelid drooping. These effects are transient and resolve within days to weeks as the Botox effect gradually diminishes. Serious adverse effects are rare when the treatment is administered by an experienced provider following the PREEMPT protocol.

Botox in the Context of Other Treatments

Botox is typically used in combination with other aspects of a comprehensive migraine management plan rather than as a standalone treatment. Acute medications remain important for managing breakthrough attacks during Botox treatment. Some patients also continue oral preventive medications alongside Botox, particularly early in treatment when the full Botox effect has not yet developed. Discussing the full treatment plan with the prescribing neurologist ensures that all components of the plan work together appropriately.